Parkinson's risk hunt: 2,200 volunteers help uncover hidden clues
NCT ID NCT03536104
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked for genetic and environmental factors that increase the risk of developing Parkinson's disease. Researchers compared DNA and lifestyle data from over 2,200 people, including Parkinson's patients, people with related brain diseases, and healthy volunteers. The goal was to find specific gene variations linked to Parkinson's and understand how they interact with things like environment and biology.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify people at higher risk for Parkinson's disease and point toward potential targets for future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find clear genetic links, and any findings will need much more research before they could help patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
2,220 people
The number who actually took part.
- Started
-
Mar 2009
- Finished
-
Nov 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with Parkinson Disease compared to subjects at risk to develop Parkinson Disease and healthy controls
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inclusion criteria for Parkinson's patients and "related diseases" controls: * Parkinsonian patients meeting the Gelb criteria * Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease). * Woman of childbearing age having an effective means of contraception. * Informed consent signed by the subject or his legal representative. * For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative. Criteria for inclusion of non-ill controls: * Absence of rest trembling, bradykinesia and stiffness * MMSE (Mini Mental State Examination) greater than 25 * Woman of childbearing age having an effective means of contraception. * subject having signed the informed consent. * No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test. Exclusion Criteria: * Criteria for non-inclusion of patients: * Clinical criteria for exclusion of the diseases described * Participation in another therapeutic trial or in the exclusion period of a previous clinical trial. Criteria for non-inclusion of non-ill controls: * Functional discomfort in daily life of unknown cause * MMSE less than 25 * Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Roger Salengro, CHRU de Lille
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Glutathione, brain metabolism and inflammation in Alzheimer's disease
- A multicenter, open-label extension (OLE) study to evaluate the safety, pharmacodynamics, and clinical effects of WVE-004 in patients with C9orf72-associated amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD)
- Individualized 130 hz subthalamic temporal interference stimulation versus medication for motor symptoms in parkinson disease
- Contrasting chronic inflammation and neurodegeneration using the human amniotic mesenchymal cell secretome as an innovative therapeutic strategy
- Parkinson's improvement activated by hula understanding (PAHU) - part 2
- Can early markers predict how atypical Parkinson's diseases progress?